Breast Imaging Market

An outpatient imaging centre deciding whether to replace a 2D unit with tomosynthesis is weighing a Medicare add-on of USD 50.78 per bilateral 3D screen on top of USD 124.53 for the base screening mammogram, and that single purchase decision, repeated across thousands of sites, sets the pace of the breast imaging market. Breast imaging covers the mammography, tomosynthesis, ultrasound, MRI, contrast and molecular systems, software and service that find and characterise breast disease. Douglas Insights sizes the global market at USD 5.62 billion in 2025 and USD 11.19 billion in 2035, a 7.12% revenue CAGR for 2026-2035, built as 91,800 installed breast imaging systems times USD 61,240 of vendor revenue per system per year. Federal rules under the Mammography Quality Standards Act (MQSA) began requiring a breast density statement in every report and patient letter when FDA enforcement of the 2023 final rule began on 10 September 2024. The study belongs to our diagnostic devices coverage and follows the Douglas Insights research methodology.

Which machines and software sit inside the breast imaging scope used here?

Breast imaging, as sized here, includes seven product lines worth USD 5.62 billion in 2025. They are digital breast tomosynthesis systems, 2D full-field digital mammography systems, breast ultrasound, handheld and automated, breast MRI, contrast-enhanced mammography and molecular breast imaging, breast imaging AI and software, and service and upgrades. Revenue is counted at the vendor, not the radiology practice.

Reading fees, radiologist professional income and screening-programme overheads are excluded. Biopsy needles and markers belong to the sibling Biopsy Devices Market, while CT, general X-ray and PET sit in the broader Diagnostic Imaging Market. Image archives that store mammograms are sized in the Cloud Based Picture Archiving and Communication Service Market. Buyers covered are hospitals, diagnostic imaging centres and breast care centres. Applications covered are screening, diagnostic workup and image-guided biopsy, the last only for the imaging hardware used to guide the needle.

Why are tomosynthesis upgrades and dense-breast letters lifting breast imaging spend?

Breast imaging volume grows 3.6% a year in our base case because screening starts earlier, density letters send more women to supplemental scans, and tomosynthesis keeps replacing 2D units. Douglas Insights splits that 3.6-point volume leg into four drivers that add up exactly.

Screening age is the largest single lever, worth 1.3 points. The US Preventive Services Task Force (USPSTF) finalised a grade B recommendation on 30 April 2024 for biennial screening mammography from age 40 to 74, so the screened cohort now begins a full decade before the age of 50. Ten extra years of eligibility per woman adds a cohort that did not previously sit in the routine screening base, and each breast imaging unit in the US already performs about 1,622 procedures a year. More screens per unit turn into more units once rooms run full, and the first new rooms go to suburban imaging centres that already run long screening waitlists.

Density notification adds 1.1 points. The MQSA amendments require every report to carry one of four density statements and every lay letter to say whether tissue is dense, a rule enforced since 10 September 2024 according to the FDA final rule page. Women told that dense tissue lowers the sensitivity of mammography ask about ultrasound or MRI, and both breast ultrasound and breast MRI fleets expand as a result. Our model gives breast ultrasound a 7.7% revenue growth rate against 5.9% for breast MRI, because ultrasound rooms are cheaper to add.

Tomosynthesis replacement adds 0.8 points. The FDA MQSA national statistics list 26,539 accredited mammography units at 8,963 certified US facilities as of 1 March 2025, of which 12,780 are accredited tomosynthesis units at 8,266 facilities. That leaves 13,759 units, or 51.8% of the US breast imaging fleet, still to be swapped or retired, and each swap counts as a new installed system in our base.

Emerging-market screening programmes add the last 0.4 points. Asia Pacific grows 9.6% a year in revenue terms in our regional model, the fastest of five regions, as public screening schemes buy their first digital mammography units. Taken together, the four contributions of 1.3, 1.1, 0.8 and 0.4 points equal the 3.6% volume leg, while realised revenue per breast imaging system rises 3.4% a year as AI licences and contrast options are added to each room. Douglas Insights expects that price leg to hold steady through 2035.

Which headwinds slow breast imaging revenue, from radiologist shortages to tender pricing?

Three restraints remove 1.9 points from what breast imaging revenue growth would otherwise reach: reading capacity, payer pricing and long replacement cycles. Without them our 7.12% revenue CAGR would sit near 9.0%, close to the top of published estimates, so the restraints explain most of the gap between our view and the more bullish forecasts.

Reading capacity takes out 0.8 points. Every extra screen needs a radiologist read, and 43,052,991 mammography procedures reported by US facilities already fill existing reading lists. Sites that cannot add readers delay a second breast imaging room even when the volume exists.

Payer pricing removes 0.6 points. The 2025 Medicare global rate for a bilateral screening mammogram is USD 124.53, and the tomosynthesis add-on is USD 50.78, so a site earns USD 175.31 per 3D screen before the professional component. Flat rates cap what a buyer will pay for a new breast imaging system, and public tenders in Europe press hardware prices further.

Replacement cycles take out 0.5 points. A breast imaging gantry commonly stays in service for close to a decade, and our model holds 2D full-field digital mammography revenue to a 1.4% annual decline as those units age out rather than being replaced early.

Which breast imaging modality leads by segment value, and which grows fastest?

Digital breast tomosynthesis systems lead breast imaging with 41.7% of 2025 revenue, or USD 2.34 billion, while breast imaging AI and software grows fastest at 16.4% a year. Tomosynthesis wins because it is now the default screening room; AI wins because it is sold per study on installed units.

Digital breast tomosynthesis systems hold USD 2.34 billion because 92.2% of certified US facilities already run at least one 3D unit and new buyers rarely order 2D-only rooms. 2D full-field digital mammography systems keep USD 691.5 million, mostly mobile vans and price-led tenders, and shrink 1.4% a year. Breast ultrasound, handheld and automated, earns USD 877.0 million as the first supplemental test after a dense-breast letter. Breast MRI brings USD 550.9 million from high-risk surveillance and staging. Contrast-enhanced mammography and molecular breast imaging total USD 230.5 million and grow 10.8% a year as cheaper alternatives to MRI.

Breast imaging AI and software is the fastest segment at 16.4% a year, rising from USD 416.0 million to USD 1.90 billion, because triage, density scoring and risk tools are licensed per study and ride on every new tomosynthesis slice stack. Service and upgrades add USD 511.6 million; Hologic notes that its breast business earns a majority of its service revenue from contracts on its digital mammography portfolio.

Where in the world are breast imaging systems being installed fastest?

Asia Pacific is the fastest-growing breast imaging region at 9.6% a year, from USD 1.35 billion in 2025 to USD 3.39 billion in 2035, while North America stays the largest at USD 2.22 billion. Organised screening programmes in populous countries explain the Asian pace; reimbursed tomosynthesis explains American size.

North America holds 39.4% of breast imaging revenue in 2025, USD 2.22 billion, rising at 6.1% to USD 4.00 billion, with the US fleet of 26,539 accredited units as its anchor. Europe follows with USD 1.51 billion and 26.8%, growing 5.6% to USD 2.60 billion as tender-driven replacement of national screening fleets keeps prices tight. Asia Pacific takes 24.1% today and 30.3% by 2035 on our numbers. Latin America accounts for USD 298.0 million, growing 7.8% to USD 631.5 million, where private imaging chains buy tomosynthesis ahead of public systems.

Middle East and Africa is the wildcard at USD 247.3 million, growing 8.59% a year to USD 563.8 million. Gulf health systems are funding women’s health centres, but sub-Saharan Africa still lacks the reading capacity to run high-volume breast imaging screening, so the regional range is wide.

Who sells mammography and breast ultrasound systems, and how concentrated is the field?

Douglas Insights estimates the top three breast imaging vendors, Hologic, GE HealthCare and Siemens Healthineers, hold 53.6% of 2025 revenue. Hologic leads with an estimated 27.6% share, anchored on disclosed breast health revenue, and installed-base service contracts keep that share sticky across replacement cycles.

Hologic reported breast health revenue of USD 393.7 million in its fiscal fourth quarter ended 27 September 2025, up 4.8%, and said it had agreed on 21 October 2025 to be acquired by funds managed by Blackstone and TPG at up to USD 79 per share. Annualising that quarter gives roughly USD 1.57 billion, which includes interventional breast products; removing those leaves our USD 1.55 billion imaging estimate. Its own annual filing names Siemens Healthineers and GE HealthCare as its large imaging competitors.

GE HealthCare holds an estimated 14.2% share built on the Pristina Via mammography platform, upgraded with the deep-learning Pristina Recon DL 3D reconstruction, plus automated breast ultrasound. Siemens Healthineers, at an estimated 11.8%, competes on the Mammomat B.brilliant; it announced FDA clearance of contrast-enhanced mammography and contrast-guided biopsy for that system on 30 June 2026. Fujifilm, at an estimated 8.7%, sells the ASPIRE Cristalle 3D system and its comfort paddle.

Software consolidation is the newest front. RadNet’s DeepHealth unit completed its purchase of iCAD on 17 July 2025, adding AI used at more than 1,500 provider locations and a reach of over 10 million mammograms a year. Lunit owns Volpara, whose density and quality tools sit in more than 2,000 US sites.

How much do buyers pay per tomosynthesis screen and per installed breast imaging system?

Douglas Insights puts realised vendor revenue at USD 61,240 per installed breast imaging system per year in 2025, rising to USD 85,554 by 2035. That figure blends hardware amortisation, service contracts and software licences, and it is the price leg behind our 3.4% annual price growth.

On the payer side, the 2025 Medicare rates are USD 124.53 for a bilateral screening mammogram, USD 50.78 for the tomosynthesis add-on, USD 153.65 for a bilateral diagnostic mammogram and USD 121.95 for a unilateral diagnostic study, all global office rates from the Hologic 2025 mammography coding guide. Professional components are USD 34.93 and USD 27.94 for the screening and tomosynthesis codes.

Our price bands for breast imaging hardware are estimates: a 2D refurbished unit sells for well under USD 150,000, a new tomosynthesis room typically clears USD 350,000 to USD 500,000 with workstation, and a contrast-capable 3D system with biopsy guidance sits above that. Breast imaging AI licences add a per-study fee that turns into tens of thousands of dollars a year at a busy site.

How do FDA MQSA rules and breast density standards shape breast imaging purchases?

MQSA governs all 8,963 certified US mammography facilities, and its 2023 amendments made density reporting mandatory nationwide from 10 September 2024. The rule pushes breast imaging buyers toward supplemental ultrasound and MRI capacity and toward software that grades density consistently.

The FDA issued the final rule on 10 March 2023, and the agency states that enforcement began 18 months later. Reports must use one of four density statements, such as the breasts being extremely dense, which lowers the sensitivity of mammography. Facilities must also tell each patient in plain language whether her tissue is dense and advise her to discuss risk with a provider.

Outside the US, breast imaging units sold in Europe carry CE marking under the Medical Device Regulation, and national screening programmes set their own quality standards for dose and image quality. Those rules raise the cost of bringing a new breast imaging gantry to market, which protects incumbents with large installed bases.

What if AI triage and contrast mammography change breast imaging volumes by 2035?

Our base case reaches USD 11.19 billion for breast imaging in 2035 on 3.6% volume and 3.4% price growth; a slower case ends at USD 9.21 billion and a faster case at USD 13.17 billion. AI reading support and contrast mammography decide which path the market takes.

The slower case uses 2.4% volume and 2.6% price growth, a 5.06% revenue CAGR, and assumes reading shortages persist and density letters lift supplemental scans less than expected. The faster case uses 4.7% volume and 4.0% price growth, an 8.89% CAGR, and assumes AI cuts read times enough for sites to add breast imaging rooms and that contrast mammography wins a broad share of supplemental imaging, helped by clearances such as the Siemens Healthineers contrast mammography clearance of 30 June 2026.

Volume is the sensitive leg. Moving annual unit growth from 3.6% to 2.6% lowers the 2035 breast imaging value to USD 10.15 billion; moving it to 4.6% lifts it to USD 12.31 billion, a swing of about USD 1.1 billion per point. Our 7.12% base rate sits inside the band of published forecasts, which runs from about 6.8% to 8.9% a year, and toward its lower half because we net out the reading-capacity restraint.

Douglas Exclusive: the breast imaging modality-fit matrix

The breast imaging modality-fit matrix is a Douglas Insights model built from 15 sourced inputs: four 2025 Medicare rates, five FDA MQSA fleet and procedure counts, two USPSTF screening parameters and four published growth estimates. It sets each modality against the fleet gap it fills and the revenue each room earns.

The matrix produces one finding a buyer can act on. At 1,622 procedures per US unit and USD 175.31 per tomosynthesis screen, a fully 3D unit earns about USD 284,000 a year in Medicare-rate technical revenue, so the 51.8% of units still on 2D represent the largest near-term breast imaging upgrade pool. Douglas Insights counts the remaining 2D units at 13,759 from the FDA figures.

Which buyers fund breast imaging: hospitals, diagnostic imaging centres or breast care centres?

Hospitals account for 52.4% of breast imaging spend in our end-user split, diagnostic imaging centres 33.9% and breast care centres 13.7%. Hospitals own MRI and biopsy suites; outpatient diagnostic imaging centres buy tomosynthesis rooms fastest because screening volumes are their core revenue.

Hospital purchasing of breast imaging is driven by capital cycles and bundled tenders, often alongside CT and X-ray. Diagnostic imaging centres, including chains such as RadNet, buy on throughput and AI-supported productivity. Breast care centres are smaller but buy contrast mammography and ultrasound to finish workups in a single visit.

How is breast imaging split across screening, diagnostic workup and image-guided biopsy?

Screening generates 61.8% of breast imaging revenue in our application model, diagnostic workup 29.6% and image-guided biopsy 8.6%. Screening dominates because USPSTF guidance now covers women from 40 to 74 every two years, roughly 18 screening rounds per woman across her eligible years.

Diagnostic workup carries the higher Medicare rate of USD 153.65 for a bilateral study and uses more ultrasound and MRI time per patient. Image-guided biopsy needs stereotactic or tomosynthesis-guided attachments, ultrasound and MRI guidance, which keeps that share of breast imaging revenue steady at under a tenth of the total.

How the model builds breast imaging receipts: what does each installed system earn?

Douglas Insights models 91,800 installed breast imaging systems in 2025 at USD 61,240 each, which equals USD 5.62 billion. The base grows to 130,750 systems and USD 85,554 per system by 2035, giving USD 11.19 billion, a 7.12% revenue CAGR in which volume and price contribute almost equally.

The installed base starts from the 26,539 accredited US units in FDA data and scales to 28.9% of the global fleet, the US share in our country model of 34 countries. Five regional models and seven segment models were reconciled to the global total: regional 2025 values sum exactly to USD 5.62 billion and segment 2035 values land within 0.03% of the global 2035 figure.

Cross-checks used 21 data points. Annualised Hologic breast health revenue implies a 27.6% leader share against our total, consistent with its installed-base position. Three published estimates for 2025, between about USD 5.2 billion and USD 6.22 billion, bracket our USD 5.62 billion within 8%. Medicare-rate revenue per US unit, at about USD 284,000, is 4.6 times our vendor revenue per system, a ratio in line with equipment taking a minority of site income.

Sources

1. US Food and Drug Administration Important information on the final rule to amend MQSA (2024)
2. US Food and Drug Administration MQSA national statistics (2025)
3. US Preventive Services Task Force Breast cancer screening final recommendation (2024)
4. Hologic / SEC EDGAR Hologic fourth quarter fiscal 2025 results (Form 8-K exhibit 99.1) (2025)
5. Hologic / SEC EDGAR Hologic Form 10-K fiscal 2025 (2025)
6. Siemens Healthineers Mammomat B.brilliant CEM FDA clearance (2026)
7. iCAD / SEC EDGAR DeepHealth completes acquisition of iCAD (Form 8-K exhibit) (2025)
8. Hologic Mammography coding guide 2025 (2025)
9. GE HealthCare Pristina Recon DL release (2025)
10. Lunit Lunit completes acquisition of Volpara (2024)
11. Fujifilm Healthcare ASPIRE Cristalle product page (2026)